Pharmacoeconomic review report: Dolutegravir (Tivicay)
Dolutegravir (Tivicay) (DTG) is being reviewed as a treatment of HIV in both treatment-naive and treatment-experienced adults and children 12 years of age and older and weighing at least 40 kg, in combination with other antiretrovirals. The recommended oral dose of DTG is 50 mg daily at a daily cost...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
August 2014, 2014
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Dolutegravir (Tivicay) (DTG) is being reviewed as a treatment of HIV in both treatment-naive and treatment-experienced adults and children 12 years of age and older and weighing at least 40 kg, in combination with other antiretrovirals. The recommended oral dose of DTG is 50 mg daily at a daily cost of $18.50 |
|---|---|
| Item Description: | "Manufacturer, ViiV Healthcare ULC." |
| Physical Description: | 1 PDF file (vi, 20 pages) illustrations |